Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**BLR250** is a Baxter-developed, two-chamber peritoneal dialysis fluid for chronic renal failure in patients receiving continuous ambulatory peritoneal dialysis. It contains a combined bicarbonate and lactate buffer system with total alkali of 35 mmol/L; separating buffer and glucose during heat sterilization/storage enables a neutral or near-neutral final dialysate with reduced glucose-degradation products. In a Japanese randomized, multicenter, open-label Phase III non-inferiority study versus Dianeal PD-4, BLR250 maintained peritoneal solute clearance and ultrafiltration while improving metabolic acidosis without apparent bicarbonate over-correction. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5648742/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BLR250.